Climb Bio Statistics
Total Valuation
Climb Bio has a market cap or net worth of $836.85 million. The enterprise value is $598.94 million.
| Market Cap | 836.85M |
| Enterprise Value | 598.94M |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Climb Bio has 57.44 million shares outstanding. The number of shares has increased by 2.38% in one year.
| Current Share Class | 57.44M |
| Shares Outstanding | 57.44M |
| Shares Change (YoY) | +2.38% |
| Shares Change (QoQ) | +11.65% |
| Owned by Insiders (%) | 0.99% |
| Owned by Institutions (%) | 78.66% |
| Float | 41.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.49 |
| P/TBV Ratio | 3.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 31.45, with a Debt / Equity ratio of 0.01.
| Current Ratio | 31.45 |
| Quick Ratio | 30.86 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -27.10% and return on invested capital (ROIC) is -18.95%.
| Return on Equity (ROE) | -27.10% |
| Return on Assets (ROA) | -18.45% |
| Return on Invested Capital (ROIC) | -18.95% |
| Return on Capital Employed (ROCE) | -26.94% |
| Weighted Average Cost of Capital (WACC) | 4.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.99M |
| Employee Count | 29 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +537.64% in the last 52 weeks. The beta is 0.08, so Climb Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | +537.64% |
| 50-Day Moving Average | 13.79 |
| 200-Day Moving Average | 8.39 |
| Relative Strength Index (RSI) | 47.71 |
| Average Volume (20 Days) | 1,224,448 |
Short Selling Information
The latest short interest is 7.56 million, so 13.16% of the outstanding shares have been sold short.
| Short Interest | 7.56M |
| Short Previous Month | 7.04M |
| Short % of Shares Out | 13.16% |
| Short % of Float | 18.16% |
| Short Ratio (days to cover) | 6.81 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -64.76M |
| Pretax Income | -57.62M |
| Net Income | -57.62M |
| EBITDA | -64.63M |
| EBIT | -64.76M |
| Earnings Per Share (EPS) | -$0.83 |
Balance Sheet
The company has $183.12 million in cash and $1.31 million in debt, with a net cash position of $237.91 million or $4.14 per share.
| Cash & Cash Equivalents | 183.12M |
| Total Debt | 1.31M |
| Net Cash | 237.91M |
| Net Cash Per Share | $4.14 |
| Equity (Book Value) | 239.55M |
| Book Value Per Share | 4.17 |
| Working Capital | 180.70M |
Cash Flow
In the last 12 months, operating cash flow was -$52.70 million and capital expenditures -$369,000, giving a free cash flow of -$53.07 million.
| Operating Cash Flow | -52.70M |
| Capital Expenditures | -369,000 |
| Depreciation & Amortization | 130,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -53.07M |
| FCF Per Share | -$0.92 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Climb Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.38% |
| Shareholder Yield | -2.38% |
| Earnings Yield | -6.89% |
| FCF Yield | -6.34% |
Analyst Forecast
The average price target for Climb Bio is $22.57, which is 54.91% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22.57 |
| Price Target Difference | 54.91% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |